Cytokinetics, Incorporated

NASDAQ:CYTK

Biotechnology

Healthcare
$51.32 +3.86%

+$2.90 today

Market cap
$7.15B
Beta
0.43
P/E (TTM)
-11.6
EPS (TTM)
-$6.73
52W Low $31.99High $80.20

Volume 1.59M

Average 2.37M

CYTK Income Before Tax

Profit after all operating and non-operating items but before income tax.

Cytokinetics, IncorporatedNASDAQ: CYTK

Income Before Tax · Q2 FY2026 · quarter ended Jun 2026

Income before tax remains negative

Q2 FY2026 income before tax was -$198.76M, compared with -$134.37M a year earlier. Trailing-twelve-month income before tax was -$894M.

Context

  • Income before tax amounted to 891.6% of revenue in FY2025, down 2299.5 pp from a year earlier.
  • Income before tax grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$198.76M or moves back toward the trailing-twelve-month quarterly average of -$223.5M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$198.76M+3.5% QoQ
Last fiscal yearDec 2025
-$784.96M-33.2% YoY
LTMJun 2026
-$894M-47.4% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-47.9%——
1 year-33.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(784.96M) USD
Year-over-year change
-33.2%

Income Before Tax vs competitors

How CYTK compares with its peers on the latest reported figures

  • CYTK's LTM Jun 2026 income before tax of -$894M is the lowest of the 3 companies compared; the peer median is -$79.92M.
  • Its year-over-year change of -47.4% is the lowest of 2, against a peer median of +21.5%.
  • Income before tax amounts to 1259.9% of revenue for CYTK, versus a peer median of 18651.9%.
CYTK Competitors Peer median
Income Before Tax for CYTK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RNAAtrium Therapeutics, Inc.FY2025-$76.83M ——412.6%
TNYATenaya Therapeutics, Inc.LTM Mar 2026-$83.01M +21.5%—36891.1%
CYTKCytokinetics, IncorporatedLTM Jun 2026-$894M -47.4%—1259.9%
KARDKardigan, Inc.—— ———
Peer median (excluding CYTK) -$79.92M+21.5%—18651.9%

Competitors are the stored peer set for CYTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue70.43M94.59M7.53M18.47M88.04M
Cost of Revenue159.94M240.81M330.12M339.41M10.13M
Gross Profit(89.51M)(146.23M)(322.59M)(320.93M)77.91M
Gross Margin-127.1%-154.6%-4284.1%-1737.2%88.5%
Research & Development159.94M240.81M330.12M339.41M405.9M
Selling, General & Admin96.8M177.98M173.61M215.31M284.27M
Operating Expenses96.8M177.98M173.61M215.31M690.17M
Depreciation & Amortization2.28M5.81M11.89M9.53M10.13M
EBITDA(183.71M)(331.99M)(456.68M)(493.48M)(774.83M)
EBITDA Margin-260.8%-351.0%-6064.9%-2671.2%-880.1%
Operating Income(186.31M)(324.2M)(496.21M)(536.25M)(612.26M)
Operating Margin-264.5%-342.8%-6589.7%-2902.7%-695.4%
Interest Income331K11.34M27.63M51.53M48.42M
Interest Expense29.33M51.16M57.67M86.51M103.87M
Other Income / Expenses(29M)(64.75M)(30.04M)(53.28M)(172.7M)
Income Before Tax(215.31M)(388.96M)(526.24M)(589.53M)(784.96M)
Pre-Tax Margin-305.7%-411.2%-6988.6%-3191.1%-891.6%
Income Tax Expense00000
Net Income(215.31M)(388.96M)(526.24M)(589.53M)(784.96M)
Net Margin-305.7%-411.2%-6988.6%-3191.1%-891.6%
EPS (Basic)(2.80)(4.33)(5.45)(5.26)(6.54)
EPS (Diluted)(2.80)(4.33)(5.45)(5.26)(6.54)
Weighted Avg Shares76.89M89.83M96.52M111.98M120.02M
Weighted Avg Shares (Diluted)76.89M89.83M96.52M111.98M120.1M

Cytokinetics, Incorporated

NASDAQ:CYTK

Intrinsic Alpha fair value

Locked

Current Price

$51.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.